Form 4: Vir Biotechnology Officer Sells Shares Under 10b5-1 Plan

Vir Biotechnology's SVP, Chief Accounting Officer, Brent Sabatini, sold 7,711 shares of common stock for $9.12 per share under a pre-arranged trading plan.

Summary

• Brent Sabatini, SVP, Chief Accounting Officer of Vir Biotechnology, Inc. (VIR), disposed of 7,711 shares of common stock.
• The transaction occurred on March 23, 2026, at a price of $9.12 per share.
• Following this sale, Sabatini beneficially owns 61,902 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on December 19, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was not a discretionary sale based on new information, and is a routine disclosure for an executive.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are common occurrences in the biotechnology sector. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, helping to avoid accusations of trading on material non-public information. This specific transaction by a Chief Accounting Officer is a routine disclosure and does not inherently signal a change in the company's operational or strategic direction.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of ownership by an executive, but given it's a 10b5-1 plan, it is generally not perceived as a negative signal regarding the company's prospects.

Key Dates

Recommendation

The sale of shares by an executive under a Rule 10b5-1 plan is a routine event and does not typically provide new material information that would warrant a change in investment recommendation. It is a pre-scheduled transaction, not a discretionary one, and therefore does not reflect a change in the executive's confidence in the company's future. Investors should continue to hold based on broader company fundamentals and market conditions, rather than this specific insider transaction.

Keywords

Vir Biotechnology, VIR, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Brent Sabatini